1 week ago
Symbiotec Pharmalab IPO Opens With Analysts Recommending Subscription
Symbiotec Pharmalab is a company that makes important ingredients used in medicines, nutrition products and specialty drugs.
It is selling shares to the public through an IPO.
Each share costs between Rs 938 and Rs 988.
The company wants to raise Rs 1,757 crore through the offering.
Several brokerages said investors could consider subscribing for the long term.
They highlighted the company’s steroidal APIs, strong customer relationships and integrated manufacturing operations.
The company’s revenue and profit increased in the financial year ended March 31, 2026.
Its grey market premium was reported at Rs 410-415 before listing.
The shares are expected to list on BSE Ltd and NSE on September 1.
The Rs 1,757 crore IPO is priced at Rs 938-988 per share and closes on August 27.
The issue comprises a Rs 150 crore fresh share sale and a Rs 1,607 crore offer-for-sale.
Brokerages including BP Equities, KC Securities, ICICIDirect and SMIFS recommended subscribing for the long term.
Symbiotec makes steroidal APIs, nutritional ingredients and specialty products, supported by vertical integration and regulatory barriers.
The grey market premium was Rs 410-415, while shares are scheduled to list on BSE Ltd and NSE on September 1.
- Who
- Symbiotec Pharmalab, an Indore-based pharmaceutical and biotechnology company, is issuing the shares; several brokerages have reviewed the offering.
- What
- The company has launched a Rs 1,757 crore IPO consisting of a fresh issue and an offer-for-sale.
- Where
- Symbiotec Pharmalab is based in Indore, and its shares are scheduled to list on BSE Ltd and NSE.
- When
- The IPO opens today, closes on Thursday, August 27, and is scheduled to list on Tuesday, September 1.
- Why
- The company is raising capital through the fresh issue, while existing shareholders are selling shares through the offer-for-sale; analysts cited its growth and diversification prospects.
Key facts
- Price band
- Rs 938-988 per equity share
- Issue size
- Rs 1,757 crore
- Issue structure
- Rs 150 crore fresh issue and Rs 1,607 crore offer-for-sale
- Lot size
- 15 equity shares, with multiples thereafter
- Financial performance
- FY26 revenue was Rs 872.26 crore and profit after tax was Rs 109.90 crore
- Grey market premium
- Rs 410-415, indicating nearly 40% potential upside according to the article
- Reservation
- 50% for institutional bidders, 35% for retail investors and 15% for HNI bidders
- Anchor investors
- 34 investors subscribed to shares worth Rs 526.2 crore at Rs 988 per share
Sources
Related news
Symbiotec Pharmalab IPO Draws Strong, Conflicting Subscription Figures
Symbiotec Pharmalabs IPO Opens With 42% Grey-Market Premium
Symbiotec Pharmalab Shares Set for Premium Market Debut
Symbiotec Pharmalab to Raise ₹1,757 Crore Through IPO
Symbiotec Pharmalab Shares Debut Near Issue Price, Recover Later
PVR Inox Buyback: September 3 Last Day to Buy
Augmont Enterprises Rises Despite Gold-Buying Appeal and Market Risks
BSE Shares Fall as New Closing Auction Session Draws Scrutiny
Spice Lounge Food Works Stock Hits Upper Circuit Amid Crash
Indian Stocks Slide as Oil, Conflict and Yields Rise
